Complete collection of bacteriophages
"Natsibio" creates an All-Russian database of bacteriophages
The collection of strains will allow the production of drugs to combat new types of bacteria
Scientific and Production Association "Microgen" National Immunobiological Company ("Natsibio") The creation of the All-Russian base of the bacteriophage strain collection for the production of antimicrobial drugs to combat new varieties of bacteria has begun. The project is being implemented within the framework of the state Strategy for Preventing the Spread of Antimicrobial Resistance in the Russian Federation for the period up to 2030.
"We are actively working with the administrations of the constituent entities of Russia in order to isolate the current strain composition of phages from the microflora of each region and form a collection. Based on it, we will be able to quickly produce bacteriophage medicines that can withstand the current composition of bacteria, including their new varieties resistant to traditional means of treatment and prevention," said Kirill Gaidash, Director General of the NGO Microgen.
Recall that in October 2017, the government approved a Strategy to prevent the spread of antimicrobial resistance in the Russian Federation for the period up to 2030. In particular, the strategy defines an action plan for the development and implementation in Russia of alternative methods, technologies, means of prevention and treatment of diseases, including the creation of biological drugs based on bacteriophages.
"We fully support the strategy adopted by the government, including initiatives to develop and introduce new means of treating and preventing diseases based on bacteriophages. In nature, they are the natural enemies of bacteria. Phages are able to mutate and fight newly emerging bacterial species, solving the problem that the world community has faced in recent years," Kirill Gaidash noted.
According to the World Health Organization, the phenomenon of antimicrobial resistance, when bacteria change and traditional drugs, including antibiotics, no longer have a proper effect on them, has been considered at the global level since 2014.
Bacteriophages are non-toxic drugs. They selectively affect only bacterial cells, and not the entire microflora of the body, unlike antibiotics. They are combined with all types of traditional antibacterial therapy and can be used even by pregnant, nursing mothers and children.
To date, Microgen is the only manufacturer of bacteriophage drugs in Russia. The company already produces more than 19 varieties of bacteriophages, annually supplying about 1 million packages to the regions of Russia for the prevention and treatment of a number of diseases, including acute intestinal diseases (dysentery, typhoid fever, salmonellosis), purulent-septic and others. The company is also working on the creation of the world's first universal bacteriophage for purulent-inflammatory ENT diseases, surgical infections, infectious diseases of children of the first year of life, intestinal dysbiosis and other diseases caused by Enterobacter bacteria.
Recall that in 2017, only in the Primorsky Territory, more than 21 thousand doses of Microgen bacteriophages were used to prevent infectious diseases in residents who fell into the flood zone in August, and were also used to save children from salmonellosis in Khakassia. In total, the use of bacteriophages over the past three years has managed to avoid outbreaks of infectious diseases in four regions of Russia affected by emergencies.
Portal "Eternal youth" http://vechnayamolodost.ru